Max Planck

As the war in Gaza continues, Germany’s unstinting defence of Israel has unleashed a culture war that has just reached Australia

Retrieved on: 
Tuesday, February 13, 2024

His work led him to being offered a stint at Germany’s prestigious Max Planck Institute for Social Anthropology.

Key Points: 
  • His work led him to being offered a stint at Germany’s prestigious Max Planck Institute for Social Anthropology.
  • This came less than two months after the Max Planck Foundation, with war in Gaza raging, had announced “additional funding for German-Israeli collaborations”.
  • What to me is a fair, intellectual critique of Israel, for them is “antisemitism according to the law in Germany”.

A political ideal

  • As he succinctly writes:
    I have a political ideal that I have always struggled for regarding Israel/Palestine.
  • It is the ideal of a multi-religious society made from
    Christians, Muslims and Jews living together on that land.
  • I have a political ideal that I have always struggled for regarding Israel/Palestine.
  • It is the ideal of a multi-religious society made from
    Christians, Muslims and Jews living together on that land.
  • His criticism of current Israeli policy, he insists, stems from the Netanyahu government’s determination to “work against such a goal”.

Self-imposed red lines

  • It is worth pointing out that it is not just happening in Germany.
  • Universities in the United States are under siege from students and community groups variously accusing them of both antisemitism and Islamophobia.
  • Largely, however, what’s happening in Germany is a result of some self-imposed red lines the German press, the German courts and the German parliament have imposed on public debate.
  • Rather, it is a result of Germany’s current belief that its genocidal, antisemitic Nazi past implies future unwavering support for Israel.
  • It might equally be said that Germany has a special responsibility to stridently oppose ethnic cleansing, war crimes and genocide wherever they occur.

Enough?

  • Sharp words from German government officials about the renewed Israeli campaign in Rafah suggest this might be possible.
  • The German Foreign Minister Annalena Baerbock warned recently “the people of Gaza cannot vanish into thin air”.


Matt Fitzpatrick receives funding from the Australian Research Council.

Updated Lab Books Help High School and College Students Learn Advanced Physics Concepts Using Data-Collection Technology

Retrieved on: 
Tuesday, January 23, 2024

BEAVERTON, Ore., Jan. 23, 2024 /PRNewswire/ -- Vernier Science Education recently updated two of its lab books, Advanced Physics with Vernier — Mechanics and Advanced Physics with Vernier — Beyond Mechanics, with investigations that utilize its award-winning Go Direct® sensors. Educators can now use the books, which collectively feature more than 40 hands-on investigations, to help high-school and college-level students learn a wide range of in-depth physics concepts using wireless data-collection technology.

Key Points: 
  • BEAVERTON, Ore., Jan. 23, 2024 /PRNewswire/ -- Vernier Science Education recently updated two of its lab books, Advanced Physics with Vernier — Mechanics and Advanced Physics with Vernier — Beyond Mechanics, with investigations that utilize its award-winning Go Direct® sensors.
  • Educators can now use the books, which collectively feature more than 40 hands-on investigations, to help high-school and college-level students learn a wide range of in-depth physics concepts using wireless data-collection technology.
  • "The hands-on investigations featured in the books are perfect for college physics, AP* Physics, or IB† Physics-level classrooms and include many extensions to challenge even the most talented students."
  • To learn more about Advanced Physics with Vernier — Beyond Mechanics, visit https://www.vernier.com/product/advanced-physics-with-vernier-beyond-mec... .

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

Retrieved on: 
Thursday, November 9, 2023

NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.

Key Points: 
  • NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.
  • The presentation will be delivered by Caleb Stokes, M.D., Ph.D. of the University of Washington at NanoSymposium (NANO22.08) on Sunday, Nov. 12, from 2:45-3:00 PM EST.
  • “With this unprecedented capability, researchers will gain critical insights into single cell signaling for healthy and diseased brain tissue.
  • The opportunity for future patient benefit is enormous,” said Brad Gray, President and CEO of NanoString.

Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, October 31, 2023

R&D expenses for the three months ended Sept. 30, 2023 amounted to $1.13 million compared to $1.19 million for the three months ended Sept. 30, 2022.

Key Points: 
  • R&D expenses for the three months ended Sept. 30, 2023 amounted to $1.13 million compared to $1.19 million for the three months ended Sept. 30, 2022.
  • Total operating expenses for the three months ended Sept. 30, 2023 amounted to $2.1 million compared to $2.1 million for the three months ended Sept. 30, 2022.
  • Financial income for the three months ended Sept. 30, 2023 amounted to $5.2 million compared to $6.9 million income for the three months ended Sept. 30, 2022.
  • As of Sept. 30, 2023, Scinai had cash and cash equivalents of $6.4 million as compared to $14.2 million as of Dec. 31, 2022.

Planck Launches the First GenAI-Enhanced Underwriting Workbench

Retrieved on: 
Monday, September 18, 2023

Planck, the trusted leader in AI-based risk research and data solutions for commercial insurers, announces the integration of powerful generative AI (GenAI) functionalities in a new underwriting workbench known as Planck PLUS.

Key Points: 
  • Planck, the trusted leader in AI-based risk research and data solutions for commercial insurers, announces the integration of powerful generative AI (GenAI) functionalities in a new underwriting workbench known as Planck PLUS.
  • “Planck PLUS is reshaping how underwriters access, analyze, and interpret risk data,” says Planck Co-Founder and CEO Elad Tsur.
  • With Planck PLUS, this transformative power is harnessed in a single, comprehensive, easy-to-use workbench built specifically for commercial insurance.
  • Planck PLUS helps underwriters navigate vast amounts of data, uncover opportunities, and enable automations to increase written premiums and improve underwriting profitability.”

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, August 11, 2023

BiondVax’s unaudited financial results will be submitted to the Securities and Exchange Commission on Form 6‑K.

Key Points: 
  • BiondVax’s unaudited financial results will be submitted to the Securities and Exchange Commission on Form 6‑K.
  • As announced previously, BiondVax has decided to leverage its aseptic manufacturing site and laboratories by creating a CDMO business unit in parallel to its innovative R&D business unit.
  • BiondVax is pursuing a strategic partnership for its COVID-19 self-administered inhaled NanoAb therapeutic/prophylactic which demonstrated highly promising in vivo results in animals.
  • BiondVax holds exclusive options for exclusive licenses at pre agreed financial terms for each of the resulting NanoAbs.

Planck Keeps Customers at the Leading Edge of GenAI Technology

Retrieved on: 
Thursday, August 10, 2023

As of July 2023, all Planck customers are leveraging the power of GenAI via the Planck online portal, launching a new era of efficiency, precision, and automation for the commercial insurance industry.

Key Points: 
  • As of July 2023, all Planck customers are leveraging the power of GenAI via the Planck online portal, launching a new era of efficiency, precision, and automation for the commercial insurance industry.
  • Planck has applied GenAI to resolve the most pressing challenges in commercial insurance underwriting.
  • Some of the key features introduced include:
    "Planck's generative AI features have revolutionized the way carriers underwrite policies,” says Planck Global Head of Insurance Leandro DalleMule.
  • “The question is not whether insurers should use GenAI, but rather how they should use it.

ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer

Retrieved on: 
Tuesday, June 20, 2023

SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief Technology Officer (CTO).

Key Points: 
  • SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief Technology Officer (CTO).
  • Throughout his career, Dr. Briggs has been leading teams to develop disruptive technological innovations in life sciences.
  • AbVitro was acquired by Juno Therapeutics, and shortly after by Bristol Myers Squibb, where Dr. Briggs led technology-focused teams.
  • “Adrian’s leadership and success in using technology to solve intractable problems ensure we remain at the forefront of technological advancements as we guide our promising therapies one step closer to the clinic,” said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
Monday, June 5, 2023

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

Planck Integrates Latest GPT Tech to Revolutionize Business Risk Analysis

Retrieved on: 
Wednesday, May 31, 2023

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Planck , the leading provider of AI-enhanced business risk data for commercial insurers, is proud to announce the integration of the latest generative pre-trained transformer (GPT) technology into its platform.

Key Points: 
  • NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Planck , the leading provider of AI-enhanced business risk data for commercial insurers, is proud to announce the integration of the latest generative pre-trained transformer (GPT) technology into its platform.
  • Commercial underwriters face significant challenges when it comes to navigating business risk research.
  • “Our mission at Planck has always been to empower commercial insurers with the tools and insights they need to navigate business risk effectively,” says Elad Tsur, co-founder and CEO of Planck.
  • “With Planck’s platform and the latest GPT, we are revolutionizing the underwriting process in commercial insurance,” says Shayna Tischler, VP of Product Development at Planck.